shine-logo

high-specific-activity

Home » high-specific-activity

SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99

Vital medical radioisotope used in over 40,000 medical diagnostic procedures [...]

2022-03-09T09:23:37-06:00January 6, 2022|News, News Releases, 2022|

SHINE, EDH enter distribution agreement for SHINE’s non-carrier-added Lu-177

SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries

SHINE Creates Therapeutics Division

SHINE Medical Technologies today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise.

2021-12-17T17:41:45-06:00October 11, 2019|News Releases, Archived, Medical Isotopes, 2019|
Go to Top